Intraindividual variability in arsenic methylation in a U.S. population

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 4, 2005, Pages 919-924

  Steinmaus, Craig ^a,b   Yuan, Yan ^a   Kalman, Dave ^c   Atallah, Raja ^c   Smith, Allan H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC DERIVATIVE; CACODYLIC ACID; INORGANIC ACID; METHANEARSONIC ACID;

ACCURACY; ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; CARCINOGENESIS; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DATA ANALYSIS; EXPOSURE; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MEDICAL ASSESSMENT; METHYLATION; POPULATION RESEARCH; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; UNITED STATES; URINALYSIS; VARIANCE;

AGED; ARSENIC; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; METHYLATION; MIDDLE AGED; REGISTRIES; SPECTROPHOTOMETRY, ATOMIC; UNITED STATES; URINARY BLADDER NEOPLASMS;

EID: 16444365005     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0277     Document Type: Article

References (58)

1. Focazio MJ, Welch AH, Watkins SA, Helsel DR, Horn MA. A retrospective analysis on the occurrence of arsenic in ground-water resources in the United States and limitations in drinking-water-supply characterizations. Reston, VA: U.S. Geological Survey; 2000. Water Resources Investigations Report 99-4279.
2. Khan AW, Ahmad SK, Sayed MH, et al. Arsenic contamination in ground water and its effect on human health with particular reference to Bangladesh. J Prev Soc Med 1997;16:65-73.
3. Luo ZD, Zhang YM, Ma L, et al. Chronic arsenicism and cancer in Inner Mongolia: consequences of well-water arsenic levels greater than 50 ug/l. In: Abernathy CO, Calderon RL, Chappel WR, editors. Arsenic: exposure and health effects. London: Chapman and Hall; 1997. p. 55-68.
4. Kurttio P, Pukkala E, Kahelin H, Auvinen A, Pekkanen J. Arsenic concentrations in well water and risk of bladder and kidney cancer in Finland. Environ Health Perspect 1999;107:1-6.
5. Cebrian ME, Albores A, Aquilar M, Blakely E. Chronic arsenic poisoning in the north of Mexico. Hum Toxicol 1983;2:121-33.
6. Hopenhayn-Rich C, Biggs ML, Fuchs A, et al. Bladder cancer mortality associated with arsenic in drinking water in Argentina [published erratum appears in Epidemiology 1997;8:334]. Epidemiology 1996;7:117-24.
7. Smith AH, Goycolea M, Haque R, Biggs ML. Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol 1998;147:660-9.
8. Chen CJ, Kuo TL, Wu MM. Arsenic and cancer [letter]. Lancet 1988;1: 414-5.
9. Chowdhury UK, Biswas BK, Chowdhury TR, et al. Groundwater arsenic contamination in Bangladesh and West Bengal, India. Environ Health Perspect 2000;108:393-7.
10. National Research Council. Subcommittee on Arsenic in Drinking Water. Arsenic in drinking water. Washington (DC): National Academy Press; 1999.
11. National Research Council (NRC). Subcommittee to Update the 1999 Arsenic in Drinking Water Report. Arsenic in drinking water 2001 update. Washington (DC): National Academy Press; 2001.
12. Smith AH, Hopenhayn-Rich C, Bates MN, et al. Cancer risks from arsenic in drinking water [see comments]. Environ Health Perspect 1992;97:259-67.
13. Chen CJ, Chen CW, Wu MM, Kuo TL. Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 1992;66:888-92.
14. Vahter M. Mechanisms of arsenic biotransformation. Toxicology 2002;181: 211-7.
15. Gebel TW. Arsenic methylation is a process of detoxification through accelerated excretion. Int J Hyg Environ Health 2002;205:505-8.
16. Styblo M, Drobna Z, Jaspers I, Lin S, Thomas DJ. The role of biomethylation in toxicity and carcinogenicity of arsenic: a research update. Environ Health Perspect 2002;110:S767-71.
17. Hopenhayn-Rich C, Smith AH, Goeden HM. Human studies do not support the methylation threshold hypothesis for the toxicity of inorganic arsenic. Environ Res 1993;60:161-77.
18. Vahter M. Variation in human metabolism of arsenic. In: Chappell WR, Abernathy CO, Calderon RL, editors. Arsenic: exposure and health effects. Amsterdam: Elsevier; 1999. p. 267-79.
19. Hopenhayn-Rich C, Biggs ML, Kalman DA, Moore LE, Smith AH. Arsenic methylation patterns before and after changing from high to lower concentrations of arsenic in drinking water. Environ Health Perspect 1996;104:1200-7.
20. Hopenhayn-Rich C, Biggs ML, Smith AH, Kalman DA, Moore LE. Methylation study of a population environmentally exposed to arsenic in drinking water. Environ Health Perspect 1996;104:620-8.
21. Hughes MF, Kenyon EM. Dose-dependent effects on the disposition of monomethylarsonic acid and dimethylarsinic acid in the mouse after intravenous administration. J Toxicol Environ Health A 1998;53:95-112.
22. Buchet JP, Lauwerys R, Roels H. Comparison of the urinary excretion of arsenic metabolites after a single oral dose of sodium arsenite, monomethylarsonate, or dimethylarsinate in man. Int Arch Occup Environ Health 1981;48:71-9.
23. Buchet JP, Lauwerys R, Roels H. Urinary excretion of inorganic arsenic and its metabolites after repeated ingestion of sodium metaarsenite by volunteers. Int Arch Occup Environ Health 1981;48:111-8.
24. Moore MM, Harrington-Brock K, Doerr CL. Relative genotoxic potency of arsenic and its methylated metabolites. Mutat Res 1997;386:279-90.
25. Mass MJ, Tennant A, Roop BC, et al. Methylated trivalent arsenic species are genotoxic. Chem Res Toxicol 2001;14:355-61.
26. Cullen WR, McBride BC, Manji H, Pickett AW, Reglinski J. The metabolism of methylarsine oxide and sulfide. Appl Organometal Chem 1989;3:71-8.
27. Styblo M, Serves S, Cullen W, Thomas D. Comparative inhibition of yeast glutathione reductase by arsenicals and arsenothiols. Chem Res Toxicol 1997;10:27-33.
28. Styblo M, Vega L, Germolec DR, et al. Metabolism and toxicity of arsenicals in cultured cells. In: Chappell WR, Abernathy CO, and Calderon RL editors. Arsenic: exposure and health effects. Amsterdam: Elsevier Science Ltd; 1999. p. 311-24.
29. Styblo M, Del Razo LM, Vega L, et al. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 2000;74:289-99.
30. Lin S, Cullen WR, Thomas DJ. Methylarsenicals and arsinothiols are potent inhibitors of mouse liver thioredoxin reductase. Chem Res Toxicol 1999;12:924-30.
31. Lin S, Del Razo LM, Styblo M, Wang C, Cullen WR, Thomas DJ. Arsenicals inhibit thioredoxin reductase in cultured rat hepatocytes. Chem Res Toxicol 2001;14:305-11.
32. Petrick JS, Ayala-Fierro F, Cullen WR, Carter DE, Aposhian VH. Monomethylarsonous acid (MMA(III)) is more toxic than arsenite in Chang human hepatocytes. Toxicol Appl Pharmacol 2000;163:203-7.
33. Chen YC, Guo YL, Su HJ, et al. Arsenic methylation and skin cancer risk in southwest Taiwan. J Occup Environ Med 2003;45:241-8.
34. Chen YC, Su HJ, Guo YL, et al. Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes Control 2003;14:303-10.
35. Del Razo LM, Garcia-Vargas GG, Vargas H, et al. Altered profile of urinary arsenic metabolites in adults with chronic arsenicism. A pilot study. Arch Toxicol 1997;71:211-7.
36. Maki-Paakkanen J, Kurttio P, Paldy A, Pekkanen J. Association between the clastogenic effect in peripheral lymphocytes and human exposure to arsenic through drinking water. Environ Mol Mutagen 1998;32:301-13.
37. Hsueh YM, Chiou HY, Huang YL, et al. Serum β-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol Biomarkers Prev 1997;6:589-96.
38. Yu RC, Hsu KH, Chen CJ, Froines JR. Arsenic methylation capacity and skin cancer. Cancer Epidemiol Biomarkers Prev 2000;9:1259-62.
39. Bates M, Rey O, Biggs M, et al. Case-control study of bladder cancer and exposure to arsenic in Argentina. Am J Epidemiol 2004;159:381-9.
40. Steinmaus C, Yuan Y, Bates MN, Smith AH. Case-control study of bladder cancer and drinking water arsenic in the western United States. Am J Epidemiol 2003;158:1193-201.
41. Calderon R, Hudgens E, Le XC, Schreinmachers D, Thomas DJ. Excretion of arsenic in urine as a function of exposure to arsenic in drinking water. Environ Health Perspect 1999;107:663-7.
42. Feldmann J, Lai VW, Cullen WR, Ma M, Lu X, Le XC. Sample preparation and storage can change arsenic speciation in human urine. Clin Chem 1999;45:1988-97.
43. Crecelius EA. Modification of the arsenic speciation technique using hydride generation. Anal Chem 1978;50:826-7.
44. Del Razo L, Aguilar C, Sierra-Santoyo A, Cebrian M, Varillas A. Interference in the quantification of methylated arsenic species in human urine. J Anal Toxicol 1999;23:103-7.
45. Del Razo LM, Styblo M, Cullen WR, Thomas DJ. Determination of trivalent methylated arsenicals in biological matrices. Toxicol Appl Pharmacol 2001;174:282-93.
46. Fleiss J. The design and analysis of clinical experiments. New York: John Wiley and Sons; 1986.
47. Hsueh YM, Ko YF, Huang YK, et al. Determinants of inorganic arsenic methylation capacity among residents of the Lanyang Basin, Taiwan: arsenic and selenium exposure and alcohol consumption. Toxicol Lett 2003;137:49-63.
48. Concha G, Vogler G, Lezcano D, Nermell B, Vahter M. Exposure to inorganic arsenic metabolites during early human development. Toxicol Sci 1998;44: 185-90.
49. Concha G, Volger G, Nermell B, Vahter M. Intra-individual variation in the metabolism of inorganic arsenic. Int Arch Occup Environ Health 2002;75:576-80.
50. Vahter M. Methylation of inorganic arsenic in different mammalian species and population groups. Sci Prog 1999;82:69-88.
51. Chung JS, Kalman DA, Moore LE, et al. Family correlations of arsenic methylation patterns in children and parents exposed to high concentrations of arsenic in drinking water. Environ Health Perspect 2002;110:729-33.
52. Vahter M. Genetic polymorphism in the biotransformation of inorganic arsenic and its role in toxicity. Toxicol Lett 2000;112-3:209-17.
53. Chiou HY, Hsueh YM, Hsieh LL, et al. Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan. Mutat Res 1997;386:197-207.
54. Vahter M, Concha G, Nermell B, Nilsson R, Dulout F, Natarajan AT. A unique metabolism of inorganic arsenic in native Andean women. Eur J Pharmacol 1995;293:455-62.
55. Weinshilboum RM. Methylation pharmacogenetics: thiopurine methyltransferase as a model system. Xenobiotica 1992;22:1055-71.
56. Weinshilboum R. Pharmacogenetics of methylation: relationship to drug metabolism. Clin Biochem 1988;21:201-10.
57. Wang Z, Zhou J, Lu X, Gong Z, Le C. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chem Res Toxicol 2004;17:95-103.
58. Mandal BK, Ogra Y, Suzuki K. Identification of dimethylarsinous and monomethylarsonous acids in human urine of the arsenic-affected areas in West Bengal, India. Chem Res Toxicol 2001;14:371-8.